Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 435

1.

Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.

Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M 3rd.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):370-7. doi: 10.1016/j.ijrobp.2012.04.028. Epub 2012 Jun 4.

PMID:
22672747
2.

Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life.

Peters M, Maenhout M, van der Voort van Zyp JR, Moerland MA, Moman MR, Steuten LM, van Deursen MJ, van Vulpen M.

Radiother Oncol. 2014 Jul;112(1):77-82. doi: 10.1016/j.radonc.2014.06.013. Epub 2014 Jul 3.

PMID:
24998704
3.

Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience.

Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach M 3rd, Hsu IC.

Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1106-12. Epub 2006 Dec 29.

PMID:
17197119
4.

Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.

Lee HK, Adams MT, Motta J.

Brachytherapy. 2008 Jan-Mar;7(1):17-21. doi: 10.1016/j.brachy.2007.11.002. Epub 2008 Jan 16.

PMID:
18201939
5.

Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.

Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, Roach M 3rd, Shinohara K.

BJU Int. 2009 Sep;104(5):600-4. doi: 10.1111/j.1464-410X.2009.08445.x. Epub 2009 Feb 23.

6.

Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.

Chen CP, Weinberg V, Shinohara K, Roach M 3rd, Nash M, Gottschalk A, Chang AJ, Hsu IC.

Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):324-9. doi: 10.1016/j.ijrobp.2013.01.027. Epub 2013 Mar 6.

PMID:
23474112
7.

Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study.

Nguyen PL, Chen MH, D'Amico AV, Tempany CM, Steele GS, Albert M, Cormack RA, Carr-Locke DL, Bleday R, Suh WW.

Cancer. 2007 Oct 1;110(7):1485-92.

8.

Rectal dose constraints for salvage iodine-125 prostate brachytherapy.

Peters M, Hoekstra CJ, van der Voort van Zyp JR, Westendorp H, van de Pol SM, Moerland MA, Maenhout M, Kattevilder R, van Vulpen M.

Brachytherapy. 2016 Jan-Feb;15(1):85-93. doi: 10.1016/j.brachy.2015.10.004. Epub 2015 Nov 21.

PMID:
26614233
9.

Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.

Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE.

Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1261-6.

PMID:
10889379
10.
11.

Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.

Zilli T, Taussky D, Donath D, Le HP, Larouche RX, Béliveau-Nadeau D, Hervieux Y, Delouya G.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e377-83. doi: 10.1016/j.ijrobp.2011.02.037. Epub 2011 Apr 20.

PMID:
21514068
12.
13.

Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity.

Henríquez I, Sancho G, Hervás A, Guix B, Pera J, Gutierrez C, Abuchaibe O, Martínez-Monge R, Tormo A, Polo A.

Radiat Oncol. 2014 Apr 30;9:102. doi: 10.1186/1748-717X-9-102.

14.

High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.

Fuller DB, Wurzer J, Shirazi R, Bridge SS, Law J, Mardirossian G.

Pract Radiat Oncol. 2015 Nov-Dec;5(6):e615-23. doi: 10.1016/j.prro.2015.04.009. Epub 2015 Jun 6.

PMID:
26059509
15.

Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.

Mbeutcha A, Chauveinc L, Bondiau PY, Chand ME, Durand M, Chevallier D, Amiel J, Kee DL, Hannoun-Lévi JM.

Radiat Oncol. 2017 Mar 9;12(1):49. doi: 10.1186/s13014-017-0789-9.

16.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768
17.

High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.

Barkati M, Williams SG, Foroudi F, Tai KH, Chander S, van Dyk S, See A, Duchesne GM.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1889-96. doi: 10.1016/j.ijrobp.2010.09.006. Epub 2011 May 6.

PMID:
21550182
18.

Salvage prostate HDR brachytherapy combined with interstitial hyperthermia for local recurrence after radiation therapy failure.

Kukiełka AM, Hetnał M, Dąbrowski T, Walasek T, Brandys P, Nahajowski D, Kudzia R, Dybek D, Reinfuss M.

Strahlenther Onkol. 2014 Feb;190(2):165-70. doi: 10.1007/s00066-013-0486-z. Epub 2013 Dec 8.

PMID:
24317192
19.

Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity.

Rose JN, Crook JM, Pickles T, Keyes M, Morris WJ.

Brachytherapy. 2015 May-Jun;14(3):342-9. doi: 10.1016/j.brachy.2015.01.002. Epub 2015 Feb 26.

PMID:
25727178
20.

Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer.

Burri RJ, Stone NN, Unger P, Stock RG.

Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1338-44. doi: 10.1016/j.ijrobp.2009.06.061.

PMID:
20138442

Supplemental Content

Support Center